These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

663 related items for PubMed ID: 25728729

  • 61. 2019 vs. 2016 ESC/EAS statin guidelines for primary prevention of atherosclerotic cardiovascular disease.
    Mortensen MB, Nordestgaard BG.
    Eur Heart J; 2020 Aug 14; 41(31):3005-3015. PubMed ID: 32227172
    [Abstract] [Full Text] [Related]

  • 62. Strategies for Primary Prevention of Coronary Heart Disease Based on Risk Stratification by the ACC/AHA Lipid Guidelines, ATP III Guidelines, Coronary Calcium Scoring, and C-Reactive Protein, and a Global Treat-All Strategy: A Comparative--Effectiveness Modeling Study.
    Galper BZ, Wang YC, Einstein AJ.
    PLoS One; 2015 Aug 14; 10(9):e0138092. PubMed ID: 26422204
    [Abstract] [Full Text] [Related]

  • 63. Cholesterol treatment and changes in guidelines in an academic medical practice.
    Schoen MW, Salas J, Scherrer JF, Buckhold FR.
    Am J Med; 2015 Apr 14; 128(4):403-9. PubMed ID: 25460526
    [Abstract] [Full Text] [Related]

  • 64. Race and Socioeconomic Differences Associated With Changes in Statin Eligibility Under the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines.
    Verma AA, Jimenez MP, Subramanian SV, Sniderman AD, Razak F.
    Circ Cardiovasc Qual Outcomes; 2017 Sep 14; 10(9):. PubMed ID: 28912201
    [Abstract] [Full Text] [Related]

  • 65. Comparison of Recommended Eligibility for Primary Prevention Statin Therapy Based on the US Preventive Services Task Force Recommendations vs the ACC/AHA Guidelines.
    Pagidipati NJ, Navar AM, Mulder H, Sniderman AD, Peterson ED, Pencina MJ.
    JAMA; 2017 Apr 18; 317(15):1563-1567. PubMed ID: 28418481
    [Abstract] [Full Text] [Related]

  • 66. Primary prevention of atherosclerotic cardiovascular disease: controversies and clinical considerations.
    Newsom LC.
    Ann Pharmacother; 2015 Apr 18; 49(4):484-93. PubMed ID: 25527102
    [Abstract] [Full Text] [Related]

  • 67. Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines.
    Steen DL, Khan I, Ansell D, Sanchez RJ, Ray KK.
    BMJ Open; 2017 Feb 17; 7(2):e013255. PubMed ID: 28213597
    [Abstract] [Full Text] [Related]

  • 68. Comparison of the European and US guidelines for lipid-lowering therapy in primary prevention of cardiovascular disease.
    Delabays B, de La Harpe R, Vollenweider P, Fournier S, Müller O, Strambo D, Graham I, Visseren FLJ, Nanchen D, Marques-Vidal P, Vaucher J.
    Eur J Prev Cardiol; 2023 Nov 30; 30(17):1856-1864. PubMed ID: 37290056
    [Abstract] [Full Text] [Related]

  • 69. Atherosclerotic cardiovascular disease risk assessment and predictors of statin use in Filipino-American Women.
    Borja-Hart N, Graff JC, Nolan VG, Wang J, Cooper-DeHoff RM, Ancheta IB.
    J Clin Pharm Ther; 2019 Aug 30; 44(4):632-639. PubMed ID: 30963623
    [Abstract] [Full Text] [Related]

  • 70. Assessing gaps in cholesterol treatment guidelines for primary prevention of cardiovascular disease based on available randomised clinical trial evidence: The Rotterdam Study.
    Pavlović J, Greenland P, Deckers JW, Kavousi M, Hofman A, Ikram MA, Franco OH, Leening MJ.
    Eur J Prev Cardiol; 2018 Mar 30; 25(4):420-431. PubMed ID: 29171772
    [Abstract] [Full Text] [Related]

  • 71. Impact of Implementing the 2013 ACC/AHA Cholesterol Guidelines on Vascular Events in a Statewide Community-Based Practice Registry.
    Egan BM, Li J, Fleming DO, White K, Connell K, Davis RA, Sinopoli A.
    J Clin Hypertens (Greenwich); 2016 Jul 30; 18(7):663-71. PubMed ID: 26606899
    [Abstract] [Full Text] [Related]

  • 72. The Burden of Statin Therapy based on ACC/AHA and NCEP ATP-III Guidelines: An Iranian Survey of Non-Communicable Diseases Risk Factors.
    Asgari S, Abdi H, Hezaveh AM, Moghisi A, Etemad K, Beni HR, Khalili D.
    Sci Rep; 2018 Mar 21; 8(1):4928. PubMed ID: 29563602
    [Abstract] [Full Text] [Related]

  • 73. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012.
    Wong ND, Young D, Zhao Y, Nguyen H, Caballes J, Khan I, Sanchez RJ.
    J Clin Lipidol; 2016 Mar 21; 10(5):1109-18. PubMed ID: 27678427
    [Abstract] [Full Text] [Related]

  • 74. Guidelines impact cholesterol management.
    Yu S, Zolfaghari K, Rascati KL, Copeland LA, Godley PJ, McNeal C.
    J Clin Lipidol; 2019 Mar 21; 13(3):432-442. PubMed ID: 30992244
    [Abstract] [Full Text] [Related]

  • 75.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 76. Implications of the US cholesterol guidelines on eligibility for statin therapy in the community: comparison of observed and predicted risks in the Framingham Heart Study Offspring Cohort.
    Andersson C, Enserro D, Larson MG, Xanthakis V, Vasan RS.
    J Am Heart Assoc; 2015 Apr 17; 4(4):. PubMed ID: 25888372
    [Abstract] [Full Text] [Related]

  • 77. Impact of the 2013 Cholesterol Guideline on Patterns of Lipid-Lowering Treatment in Patients with Atherosclerotic Cardiovascular Disease or Diabetes After 1 Year.
    Tran JN, Kao TC, Caglar T, Stockl KM, Spertus JA, Lew HC, Solow BK, Chan PS.
    J Manag Care Spec Pharm; 2016 Aug 17; 22(8):901-8. PubMed ID: 27459652
    [Abstract] [Full Text] [Related]

  • 78. Assessing Changes in Statin Prescribing Patterns Surrounding the 2013 American College of Cardiology/American Heart Association Lipid Guidelines.
    Kelly KE, Jiroutek MR, Lewis K, Zagar B.
    Clin Ther; 2019 Feb 17; 41(2):314-321. PubMed ID: 30686571
    [Abstract] [Full Text] [Related]

  • 79. Impact of Replacing the Pooled Cohort Equation With Other Cardiovascular Disease Risk Scores on Atherosclerotic Cardiovascular Disease Risk Assessment (from the Multi-Ethnic Study of Atherosclerosis [MESA]).
    Qureshi WT, Michos ED, Flueckiger P, Blaha M, Sandfort V, Herrington DM, Burke G, Yeboah J.
    Am J Cardiol; 2016 Sep 01; 118(5):691-6. PubMed ID: 27445216
    [Abstract] [Full Text] [Related]

  • 80. Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) guidelines for management of dyslipidemia and cardiovascular disease risk reduction: Putting evidence in context.
    Al Rifai M, Blumenthal RS, Stone NJ, Schofield RS, Orringer CE, Michos ED, Heidenreich PA, Braun L, Birtcher KK, Smith SC, Nambi V, Grundy S, Virani SS.
    Prog Cardiovasc Dis; 2021 Sep 01; 68():2-6. PubMed ID: 34371083
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.